Trefoil Therapeutics, Inc.
Trefoil is a proud sponsor of ARVO.
Trefoil Therapeutics is a clinical stage company focused on the application of novel engineered FGF1 compounds in underserved ophthalmic disease areas. The lead compound, TTHX1114, stimulates protection, migration and proliferation corneal endothelial and epithelial cells. Trefoil completed a proof-of-concept study (STORM) in 2022 investigating the use of TTHX1114 as an adjunct to the Descemet Stripping Only (DSO) procedure. This study demonstrated accelerated recovery of vision and reduction of edema versus surgery conducted without an adjunctive therapeutic agent. Based on the results shown for patients with concomitant cataract surgery in this trial, Trefoil will move forward with a phase 2 trial to evaluate the prophylactic use of TTHX1114 in patients at risk of corneal decompensation following cataract surgery. Trefoil has initiated a phase 1 study for the topical epithelial indication for the treatment of ulcerative corneal conditions and plans to enter phase 2 trials in 2023.